Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., Cloughesy, T. F., Burris, H. A., Maher, E. A., … Wen, P. Y. (2018). Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. In Journal of Clinical Oncology (Vol. 36, pp. 2002–2002). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.2002

Mellinghoff, Ingo K., Marta Penas-Prado, Katherine B. Peters, Timothy Francis Cloughesy, Howard A. Burris, Elizabeth A. Maher, Filip Janku, et al. “Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.” In Journal of Clinical Oncology, 36:2002–2002. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2002.

Mellinghoff IK, Penas-Prado M, Peters KB, Cloughesy TF, Burris HA, Maher EA, et al. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2002–2002.

Mellinghoff, Ingo K., et al. “Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 2002–2002. Crossref, doi:10.1200/jco.2018.36.15_suppl.2002.

Mellinghoff IK, Penas-Prado M, Peters KB, Cloughesy TF, Burris HA, Maher EA, Janku F, Cote GM, De La Fuente MI, Clarke J, Steelman L, Le K, Zhang Y, Sonderfan A, Hummel D, Schoenfeld S, Yen K, Pandya SS, Wen PY. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2002–2002.